Zobrazeno 1 - 10
of 665
pro vyhledávání: '"Jack, Hirsh"'
Autor:
Tim A.C. de Vries, Jack Hirsh, Vinai C. Bhagirath, Jeffrey S. Ginsberg, Ron Pisters, Martin E.W. Hemels, Joris R. de Groot, John W. Eikelboom, Noel C. Chan
Publikováno v:
TH Open, Vol 06, Iss 01, Pp e10-e17 (2022)
Background Patients with atrial fibrillation (AF) are frequently treated with apixaban 2.5-mg twice daily (BID) off-label, presumably to reduce the bleeding risk. However, this approach has the potential to increase the risk of ischemic stroke. If a
Externí odkaz:
https://doaj.org/article/f87c125f88c94373a7291ef797fbcf64
Autor:
Krishnan Shyamkumar, Jack Hirsh, Vinai C. Bhagirath, Jeffrey S. Ginsberg, John W. Eikelboom, Noel C. Chan
Publikováno v:
TH Open, Vol 05, Iss 01, Pp e84-e88 (2021)
Introduction Dose adjustment based on laboratory monitoring is not routinely recommended for patients treated with rivaroxaban but because an association has been reported between high drug level and bleeding, it would be of interest to know if measu
Externí odkaz:
https://doaj.org/article/01e5331aa7794158b71ec6328a1ef66f
Publikováno v:
Seminars in thrombosis and hemostasis, 49(3), 242-254. Thieme Medical Publishers
Anticoagulant therapy is the cornerstone of treatment and prevention of arterial and venous thromboembolism. Taking a historical perspective, starting in the 1960s, and progressing through to 2022, we discuss key clinical trials of anticoagulants tha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92840feed2dc515bb86dfcc35fceed25
https://doi.org/10.1055/s-0042-1760330
https://doi.org/10.1055/s-0042-1760330
Publikováno v:
BMC Public Health, Vol 17, Iss 1, Pp 1-10 (2017)
Abstract Background The media serves as an important link between medical research, as reported in scholarly sources, and the public and has the potential to act as a powerful tool to improve public health. However, concerns about the reliability of
Externí odkaz:
https://doaj.org/article/405dd7e31e954bed826c7a7bb3f57bf4
Publikováno v:
Canadian Journal of Cardiology. 38:588-600
Peripheral artery disease is 1 of 3 major clinical manifestations of atherosclerosis, the other 2 being coronary artery and cerebrovascular disease. Despite progress in surgery, antithrombotic therapy and therapies that modify conventional risk facto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::726ffc43704ef788122fa9e832c2acad
https://doi.org/10.1016/j.cjca.2022.01.026
https://doi.org/10.1016/j.cjca.2022.01.026
Autor:
Paul Y. Kim, Calvin H. Yeh, Brian J. Dale, Beverly A. Leslie, Alan R. Stafford, James C. Fredenburgh, Jack Hirsh, Jeffrey I. Weitz
Publikováno v:
TH Open, Vol 02, Iss 02, Pp e190-e201 (2018)
Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time. To investigate this phenomenon, we used a
Externí odkaz:
https://doaj.org/article/4f047f8b39114affb255507bb976a3e4
Autor:
Vinai C. Bhagirath, John W. Eikelboom, Jack Hirsh, Michiel Coppens, Jeffrey Ginsberg, Thomas Vanassche, Fei Yuan, Noel Chan, Salim Yusuf, Stuart J. Connolly
Publikováno v:
TH Open, Vol 01, Iss 02, Pp e139-e145 (2017)
Abstract Background In patients with nonvalvular atrial fibrillation (AF), apixaban is given in doses of 5 or 2.5 mg twice daily, according to clinical characteristics. The usual on-treatment range of apixaban drug levels, as determined by apixaban
Externí odkaz:
https://doaj.org/article/00d50671beed440c8c5d7af11cf31d56
Autor:
Noel C. Chan, Jeffrey S. Ginsberg, Krishnan Shyamkumar, Vinai Bhagirath, John W. Eikelboom, Jack Hirsh
Publikováno v:
TH Open, Vol 05, Iss 01, Pp e84-e88 (2021)
TH Open: Companion Journal to Thrombosis and Haemostasis
TH Open: Companion Journal to Thrombosis and Haemostasis
Introduction Dose adjustment based on laboratory monitoring is not routinely recommended for patients treated with rivaroxaban but because an association has been reported between high drug level and bleeding, it would be of interest to know if measu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8cca3580a2754a336e745d763630d041
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1721734
http://www.thieme-connect.de/DOI/DOI?10.1055/s-0040-1721734
Autor:
Tim A. C. de Vries, Jeffrey S. Ginsberg, Imaad Mallick, Noel C. Chan, John W. Eikelboom, Paul C Kruger, Vinai Bhagirath, Jack Hirsh, Ke Xu
Publikováno v:
Thrombosis and haemostasis. 120(9)
Background Recent reports suggest an important contribution from frequent off-label use of apixaban 2.5 mg twice daily to the higher rates of thromboembolic events observed in observational studies (OSs) relative to in randomized controlled trials (R
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51631b0d9e2487a4276110f2563adac2
https://pubmed.ncbi.nlm.nih.gov/32668484
https://pubmed.ncbi.nlm.nih.gov/32668484
Autor:
Krishnan Shyamkumar, John W. Eikelboom, Jeffrey S. Ginsberg, Rafael Diaz, Smita Sinha, Jack Hirsh, Noel C. Chan, Vinai Bhagirath, Ke Xu
Publikováno v:
Future cardiology. 17(1)
Until recently, attempts to improve the benefit of aspirin by adding another antithrombotic agent have not resulted in a mortality reduction in patients with chronic symptomatic atherosclerosis. In this population, COMPASS is the only one among six t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::002bde75900119ee8f68339f37c193b0
https://pubmed.ncbi.nlm.nih.gov/32559114
https://pubmed.ncbi.nlm.nih.gov/32559114